Lantheus Gets FDA Clearance for Automated Bone Scan Solution

November 16, 2020

Lantheus has secured 510(k) marketing clearance from the FDA for its artificial intelligence (AI)-enabled software for analysis of bone-scan images from prostate cancer patients.

The software, which calculates an automated bone-scan index (aBSI) used to manage advanced prostate cancer, will be integrated into GE Healthcare’s Xeleris workstation, Lantheus said.

The AI software has been trained to detect hotspots in bone that indicate metastatic disease and to calculate the aBSI, offering an alternative to manual interpretation of images.

View today's stories